Am J Cardiol 2004;93:356 9. 66. Zucker ML, Koster A, Prats J, Laduca FM. Sensitivity of a modi ed ACT test to levels of bivalirudin used during cardiac surgery. J Extra Corpor Technol 2005;37:364 8. 67. Merry AF. Focus on thrombin: alternative anticoagulants. Semin Cardiothorac Vasc Anesth 2007;11:256 60. 68. Nagle EL, Tsu LV, Dager WE. Bivalirudin for anti- coagulation during hypothermic cardiopulmonary bypass and recombinant factor VIIa for iatrogenic coagulopathy. Ann Pharmacother 2011;45:e47. 69. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin anti- bodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007;83:572 7. 70. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006;131:533 9. 71. Stratmann G, deSilva AM, Tseng EE, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a pa- tient with heparin-induced thrombocytopenia. Anesth Analg 2004;98:1635 9. 72. Koster A, Buz S, Krabatsch T, et al. Effect of modi ed ul- tra ltration on bivalirudin elimination and postoperative blood loss after on-pump coronary artery bypass grafting: assessment of different ltration strategies. J Card Surg 2008;23:655 8. 73. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice- evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013;28:145 284. 74. Welsby IJ, Um J, Milano CA, Ortel TL, Arepally G. Plas- mapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 2010;110:30 5. 75. Warkentin TE, Sheppard JA, Chu FV, Kapoor A, Crowther MA, Gangji A. 